XPH:NYE-SPDR® S&P Pharmaceuticals ETF (USD)

ETF | Health |

Last Closing

USD 45.05

Change

+0.16 (+0.36)%

Market Cap

N/A

Volume

0.08M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-12 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-0.21 (-0.14%)

USD 37.80B
FHLC Fidelity® MSCI Health Care In..

-0.04 (-0.06%)

USD 2.66B
FXH First Trust Health Care AlphaD..

-0.73 (-0.68%)

USD 1.05B
XHE SPDR® S&P Health Care Equipme..

-1.13 (-1.23%)

USD 0.21B
IDNA iShares Genomics Immunology an..

+0.20 (+0.90%)

USD 0.12B
SBIO ALPS Medical Breakthroughs ETF

+0.39 (+1.23%)

USD 0.09B
XHS SPDR® S&P Health Care Service..

-0.33 (-0.33%)

USD 0.07B
HTEC Robo Global® Healthcare Techn..

+0.06 (+0.20%)

USD 0.05B
BBP Virtus LifeSci Biotech Product..

+0.44 (+0.72%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

+0.34 (+1.61%)

USD 6.89M

ETFs Containing XPH

INAV 10.31 % 0.00 %

N/A

N/A
MSSS Northern Lights Fund Trus.. 10.12 % 0.00 %

-0.04 (-0.14%)

USD 0.11B

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 4.79% 57% F 74% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.79% 57% F 74% C
Trailing 12 Months  
Capital Gain 2.29% 57% F 42% F
Dividend Return 1.54% 100% F 26% F
Total Return 3.84% 62% D 33% F
Trailing 5 Years  
Capital Gain -3.53% 24% F 44% F
Dividend Return 5.50% 68% D+ 15% F
Total Return 1.97% 29% F 31% F
Average Annual (5 Year Horizon)  
Capital Gain -1.81% 19% F 24% F
Dividend Return -1.05% 19% F 16% F
Total Return 0.76% 68% D+ 19% F
Risk Return Profile  
Volatility (Standard Deviation) 15.83% 62% D 64% D
Risk Adjusted Return -6.63% 19% F 17% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.